Indian Heart Journal (Jan 2021)

Twelve-months clinical outcomes of biodegradable polymer-coated sirolimus-eluting coronary stent in real-world patients: A single-center experience.

  • Pankaj Jariwala, MD, DNB, DNB, MNAMS, FICPS, FACC, FSCAI, Fellowship in Interventional Cardiology (ICPS, Paris, France),
  • Rohithreddy Poondru, MD, DM,
  • Guru Prakash Avvuri, MD, DM,
  • Narasa Raju Kavalipati, MD, DM,
  • Pramod Kumar Kuchulakanti, MD, DM

Journal volume & issue
Vol. 73, no. 1
pp. 114 – 116

Abstract

Read online

This study was designed to evaluate the safety and performance of Metafor™ SES in real-world patients with coronary artery disease. This was retrospective, single-centre, post-marketing, observational study. The primary endpoint was the occurrence of major adverse cardiac event (MACE). A total of 141 patients (187 lesions) were treated with the study device. The average stent length and diameter was 24.75 ± 9.50 mm and 2.93 ± 0.38 mm, respectively. The cumulative incidence of MACE was 1.42%. No incidence of stent thrombosis was observed at 12-months follow-up. This retrospective study demonstrated favourable safety and performance of Metafor™ SES.

Keywords